---
title: "華潤醫藥旗下哮喘吸入粉霧劑獲 FDA 批上市"
description: "華潤醫藥公佈，集團旗下潤生藥業提交的沙美特羅替卡松吸入粉霧劑獲得美國食品藥品監督管理局 (FDA) 上市批准，是 FDA 首次批准來自中國藥企自主研發的吸入粉霧劑。沙美特羅替卡松吸入粉霧劑以聯合用藥形式 (支氣管擴張劑與吸入糖皮質激素)，用於可逆的氣道阻塞性氣道疾病的規律治療，包括成人和兒童哮喘。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/272792273.md"
published_at: "2026-01-16T06:13:29.000Z"
---

# 華潤醫藥旗下哮喘吸入粉霧劑獲 FDA 批上市

> 華潤醫藥公佈，集團旗下潤生藥業提交的沙美特羅替卡松吸入粉霧劑獲得美國食品藥品監督管理局 (FDA) 上市批准，是 FDA 首次批准來自中國藥企自主研發的吸入粉霧劑。沙美特羅替卡松吸入粉霧劑以聯合用藥形式 (支氣管擴張劑與吸入糖皮質激素)，用於可逆的氣道阻塞性氣道疾病的規律治療，包括成人和兒童哮喘。

華潤醫藥 (03320.HK) 公佈，集團旗下潤生藥業提交的沙美特羅替卡松吸入粉霧劑獲得美國食品藥品監督管理局 (FDA) 上市批准，是 FDA 首次批准來自中國藥企自主研發的吸入粉霧劑。

沙美特羅替卡松吸入粉霧劑以聯合用藥形式 (支氣管擴張劑與吸入糖皮質激素)，用於可逆的氣道阻塞性氣道疾病的規律治療，包括成人和兒童哮喘。

### Related Stocks

- [03320.HK - 華潤醫藥](https://longbridge.com/zh-HK/quote/03320.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 10:31 ETRespiratory Care Devices Market to Reach $47.9 billion, Globally, by 2033 at 7.6% CAGR: Allied Market Research | The global respiratory care devices market is projected to grow from $22.9 billion in 2023 to $47.9 billion by 2033, at  | [Link](https://longbridge.com/zh-HK/news/275778433.md) |
| Anta Sports Products gets written shareholders' approvals from Anta International, units | Anta Sports Products gets written shareholders' approvals from Anta International, units | [Link](https://longbridge.com/zh-HK/news/275885036.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/zh-HK/news/275851575.md) |
| A sexually transmitted ringworm is spreading in one US state | Minnesota is experiencing the largest outbreak of sexually transmitted ringworm (TMVII) in the U.S., with over 30 confir | [Link](https://longbridge.com/zh-HK/news/275977276.md) |
| BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study | Shares of Upstream Biosurged 20% to $32.64 in premarket trading following positive results from a mid-stage study of its | [Link](https://longbridge.com/zh-HK/news/275596211.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。